Benitec Biopharma (BNTC) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Benitec Biopharma (BNTC) over the past year, losing 39.5% versus a loss of 48.2%. Benitec Biopharma is the larger company by market cap ($282.9 million vs $266.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | CTNM |
|---|---|---|
| Share price | $8.11 | $7.08 |
| Market cap | $282.90M | $266.36M |
| 1-day change | -4.14% | -10.38% |
| YTD return | -39.79% | -38.06% |
| 1-year return | -48.18% | -39.49% |
| 5-year return | -86.52% | — |
| EPS (TTM) | $-0.98 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-45.55M | $-59.98M |
| 52-week high | $16.76 | $17.79 |
| 52-week low | $8.06 | $6.95 |
| Distance from 52-week high | -51.61% | -60.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +200.00% | +212.71% |
| Average volume | 162.32K | 732.62K |
| Shares outstanding | 34.88M | 32.96M |
| Employees | 24 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
BNTC vs CTNM FAQ
Which is bigger, Benitec Biopharma or Contineum Therapeutics?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $282.90M compared with $266.36M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, BNTC or CTNM?
CTNM returned -39.49% over the past 12 months, compared with -48.18% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.